AI Terminal
Spexis AG
Board/Management Information • Nov 20, 2019
957_rns_2019-11-20_22051165-634e-4cfa-a0bd-fe3f13812a96.html
Board/Management Information
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 20 November 2019 07:00
Polyphor announces changes to its Board of Directors
Polyphor AG / Key word(s): Personnel
20-Nov-2019 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Allschwil, Switzerland, November 20, 2019
Polyphor announces changes to its Board of Directors
Polyphor AG (SIX: POLN) announced today that Chairman of the Board Argeris “Jerry” Karabelas has resigned from the company for personal reasons, effective immediately. Kuno Sommer, Vice-Chairman of the Board, has been appointed Chairman until the next Annual General Meeting. Andreas Wallnöfer, Board member since 2016, was appointed as Vice Chairman.
“Jerry has been instrumental in Polyphor’s achievements since his appointment as Chairman in 2013. His professional expertise, excellent network in the pharmaceutical industry and enthusiasm for developing our business strategy has been invaluable,” says Kuno Sommer, Chairman of the Board of Directors. “On behalf of the entire Polyphor organization, I want to express my gratitude to Jerry for his contributions to Polyphor over the past six years. Thanks in large part to his vision, energy and passion, Polyphor has progressed to a listed company with a Phase III program. We wish Jerry and his family the very best.”
Andreas Wallnöfer is a Senior R&D Executive and former Head of Clinical Research & Exploratory Development at F. Hoffmann-La Roche Ltd.
“I am pleased of the progress made by Polyphor over the past six years in advancing the pipeline and transitioning from a macromolecule research collaboration model to development of its own pipeline of important molecules, especially balixafortide which is in the Phase III stage for the treatment of metastatic breast cancer. Also noteworthy was the very successful IPO in 2018. Though I am resigning for personal reasons, I remain confident the board, under Kuno Sommer’s chairmanship, and management under CEO Giacomo Di Nepi’s leadership will further advance Polyphor’s opportunities,” comments Argeris Karabelas.
For further information please contact:
For Investors:
Hernan Levett
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: [email protected]
For Media:
Alexandre Müller
Dynamics Group AG
Tel: +41 43 268 32 31
Email: [email protected]
About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer, and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company’s lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com .
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=SLIFBQDVII
Document title: Polyphor_20.11.2019
End of ad hoc announcement
| Language: | English |
| Company: | Polyphor AG |
| Hegenheimermattweg 125 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | +41 61 567 1600 |
| Fax: | +41 61 567 1601 |
| E-mail: | [email protected] |
| Internet: | www.polyphor.com |
| ISIN: | CH0106213793 |
| Valor: | POLN |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 916937 |
| End of Announcement | EQS Group News Service |